Literature DB >> 12967138

Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.

Mei-Ling Kuo1, Hwa-Shin Hwang, Patrick R Sosnay, Keith A Kunugi, Timothy J Kinsella.   

Abstract

PURPOSE: Ribonucleotide reductase is the rate-limiting enzyme in the de novo synthesis of deoxyribonucleotide triphosphates, which are utilized in both DNA synthesis and DNA repair. We reported previously that RR enzyme activity and R2 (catalytic subunit of RR) protein levels were increased after exposure to ionizing radiation (IR) in growth-arrested human tumor cells, suggesting that R2 protein expression regulates RR activity to allow for IR damage repair. Using isogenic human nasopharyngeal carcinoma cells in this study, we examine the relationship of overexpression of either the R1 regulatory subunit or the R2 catalytic subunit of RR to the cellular response of IR damage.
MATERIALS AND METHODS: We used three isogenic human nasopharyngeal cancer cell lines previously derived by Zhou et al, including KB, the parental tumor cell line; KB/M1, an R1 protein-overexpressing clone stably transfected with human R1 complementary DNA; and KB/M2, a R2 protein-overexpressing clone stably transfected with human R2 complementary DNA. We initially characterized these isogenic human tumor cell lines in exponential growth for R2 protein expression, RR enzyme activity, and R2 protein changes during the cell cycle by flow cytometry. Subsequently, the IR response in these cell lines was determined by clonogenic survival, cell cycle changes occurring after IR, and an analysis of IR DNA damage determined by pulsed field gel electrophoresis. The effect of combining IR and hydroxyurea, a RR (R2) inhibitor, was also studied in KB and KB/M2 cells.
RESULTS: KB/M2 cells were found to have 4.5-fold higher R2 protein expression and a threefold higher RR enzyme activity in exponential growth than KB and KB/M1. Although R2 protein levels increased at the G1/S transition in all cell lines, KB/M2 cells also demonstrated consistently higher R2 protein levels throughout the cell cycle. Using a linear-quadratic analysis of IR clonogenic survival data, KB/M2 cells were more radioresistant than KB and KB/M1 cells, including both decreased alpha and decreased beta values, a finding that correlates with increased reparable IR damage. KB/M2 cells also show a reduced G2 cell cycle arrest and fewer DNA double strand breaks 18 hours after IR (6 Gy). Exposure of KB/M2 cells to hydroxyurea (300 microM) after exposure to IR restored in vitro radiosensitivity in a manner similar to that found in KB and KB/M1 cells. DISCUSSION: An increase in R2 protein levels and RR activity in KB/M2 cells results in IR resistance, which appears mediated by enhanced IR damage repair during G2. R1 protein overexpression in these isogenic human tumor cells (KB/M1) did not affect RR activity or IR response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967138     DOI: 10.1097/00130404-200307000-00010

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  13 in total

1.  A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.

Authors:  Ludmila Katherine Martin; John Grecula; Guang Jia; Lai Wei; Xiangyu Yang; Gregory A Otterson; Xin Wu; Erica Harper; Cheryl Kefauver; Bing-Sen Zhou; Yun Yen; Mark Bloomston; Michael Knopp; S Percy Ivy; Michael Grever; Tanios Bekaii-Saab
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-17       Impact factor: 7.038

2.  Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Authors:  Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

3.  Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella
Journal:  Radiat Res       Date:  2010-09-10       Impact factor: 2.841

4.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

5.  Integrated Bioinformatics for Radiation-Induced Pathway Analysis from Proteomics and Microarray Data.

Authors:  Zhang-Zhi Hu; Hongzhan Huang; Amrita Cheema; Mira Jung; Anatoly Dritschilo; Cathy H Wu
Journal:  J Proteomics Bioinform       Date:  2008-05

6.  Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.

Authors:  Jill Kolesar; Wei Huang; Jens Eickhoff; Kristine Hahn; Dona Alberti; Steven Attia; William Schelman; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding
Journal:  Cancer Chemother Pharmacol       Date:  2008-10-22       Impact factor: 3.333

7.  Dif1 controls subcellular localization of ribonucleotide reductase by mediating nuclear import of the R2 subunit.

Authors:  Xiaorong Wu; Mingxia Huang
Journal:  Mol Cell Biol       Date:  2008-10-06       Impact factor: 4.272

8.  Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

Authors:  Yong-Wei Zhang; Tamara L Jones; Scott E Martin; Natasha J Caplen; Yves Pommier
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

9.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.

Authors:  Yangzom Doma Bhutia; Sau Wai Hung; Madeline Krentz; Dimal Patel; Dylan Lovin; Radhika Manoharan; J Michael Thomson; Rajgopal Govindarajan
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.